| Oncogenic Y641 mutations in EZH2 prevent Jak2/beta-TrCP-mediated degradation. | None |
| Results demonstrate that JAK2 deficiency delays tumor formation in GH-transgenic mice, which is linked to insignificant oncogenic STAT3 signaling and reduced reactive oxygen species-induced oxidative damage. | None |
| Targeting of SOCS2 by miR-194 resulted in derepression of the oncogenic kinases FLT3 and JAK2, leading to enhanced ERK and STAT3 signaling. | None |
| these results reveal proteome alterations in MPN granulocytes depending on the phenotype and genotype of patients, highlighting new oncogenic mechanisms associated with JAK2 mutations and overexpression of calreticulin | None |
| These findings identify oncogenic cooperativity between Jak2V617F-driven MPN and Dnmt3a loss, leading to activation of HSPC enhancer-driven inflammatory signaling. | None |
| JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor. | None |
| Role of the vav proto-oncogene product (Vav) in erythropoietin-mediated cell proliferation and phosphatidylinositol 3-kinase activity. | None |